AVL-292

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
012320122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)-cross… (More)
  • table 1
Is this relevant?
2016
2016
We have reported that a novel isoform of BTK (BTK-C) expressed in breast cancer protects these cells from apoptosis. In this… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Based on the pyrimidine skeleton of EGFRT790M inhibitors, a series of N,9-diphenyl-9H-purin-2-amine derivatives were identified… (More)
Is this relevant?
2015
2015
Bruton's tyrosine kinase (Btk) is intricately involved in anti-apoptotic signaling pathways in cancer and in regulating innate… (More)
Is this relevant?
2015
2015
Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that has mainly been studied in haematopoietic cells. We have… (More)
Is this relevant?
Review
2014
Review
2014
BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the… (More)
Is this relevant?
2012
2012
volume 30 number 3 march 2012 nature biotechnology to publish the structure of AVL-292. But it is unconcerned about a recent… (More)
  • table 1
Is this relevant?
2012
2012
On January 26, Celgene, of Summit, New Jersey, announced it would pay an initial $350 million for Avila Therapeutics. The… (More)
  • table 1
Is this relevant?
Review
2012
Review
2012
INTRODUCTION In the last few years, several tyrosine kinase inhibitors (TKIs) have been synthesized and become available for… (More)
Is this relevant?